Table 1. WHO Classification: Comparison to WHO 2010 and 2017.
WHO 2010 | Mitoses/10 HPF* | Ki-67 Index* | WHO 2017 | Mitoses/10 HPF* | Ki-67 Index* |
---|---|---|---|---|---|
Well-differentiated NENs | Well-differentiated NENs | ||||
NET grade 1 | < 2 | < 3 | NET grade 1 | < 2 | < 3 |
NET grade 2 | 2–20 | 3–20 | NET grade 2 | 2–20 | 3–20 |
NET grade 3 | > 20 | > 20 | |||
Poorly differentiated NENs | Poorly differentiated NENs | ||||
NEC (small-cell or large-cell), grade 3 | > 20 | > 20 | NEC grade 3 | > 20 | > 20 |
Small-cell type | |||||
Large-cell type | |||||
MANEC | MiNEN* |
*MiNENs may have non-endocrine component other than adenocarcinoma, e.g., squamous cell carcinoma or acinar cell carcinoma. To qualify as MiNEN, each component must be at least 30%. HPF = high power fields, MANEC = mixed adenoneuroendocrine carcinoma, MiNEN = mixed endocrine non-endocrine neoplasm, NEC = neuroendocrine carcinoma, NEN = neuroendocrine neoplasm, NET = neuroendocrine tumor, WHO = World Health Organization